Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

Yi, Jing; Thongprasert, Sumitra; Doval, Dinesh Chandra; Lee, J.; Cho, M. N.; Park, S. H.; Park, J. O.; Park, Y. S.; Kang, Wanying; Lim, Hyunji

doi:10.1200/jco.2011.29.15_suppl.e14653

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of advanced biliary tract tumors, Jun Ho Yi et al believed that sunitinib monotherapy had a poor clinical effect. The PFS was only 1.7 months, and the incidence of grade 3-4 toxicities was high (46.4%) (101). Dreyer C et al reported three cases of ICC patients with tumor progression after receiving first-line chemotherapy and treated them with sunitinib.…”

Section: Monotherapy Regimensmentioning

confidence: 99%

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Biliary tract cancers (BTCs), including cholangiocarcinoma (CCA) and gallbladder cancer (GC), are malignancies originating from the biliary tract with poor prognosis. In the early stage of BTCs, surgery is the only choice for cure. Unfortunately, most patients with BTC are diagnosed at an advanced stage and lose the opportunity for surgery. For many advanced solid tumors, antiangiogenic therapy has achieved encouraging results. While most clinical studies on antiangiogenic therapy in advanced BTCs have shown an excellent disease control rate (DCR), the improvement in overall survival (OS) is controversial. Understanding how the relevant signaling molecules influence the angiogenic response and the functional interaction is necessary for the formulation of new treatment regimens and the selection of enrolled patients. In this review, we aim to summarize and discuss the latest advances in antiangeogenesis for BTCs, mainly focusing on the molecular mechanism of angiogenesis in BTCs and the therapeutic effects from clinical trials. Furthermore, the horizon of antiangiogenesis for BTCs is highlighted.

show abstract

Section: Monotherapy Regimensmentioning

confidence: 99%

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…A phase II study of gemcitabine, oxaliplatin, and bevacizumab in advanced BTC reported a response rate of 40%, median PFS of 7 months, and OS of 12.7 months (Table 4) [79]. A single-arm phase II trial of erlotinib and bevacizumab without traditional cytotoxic Other antiangiogenic agents such as sorafenib and sunitinib have failed to show efficacy in this disease, either as single agents or in combination with gemcitabine, with response rates ,10% and survival times less than that seen with other regimens [81][82][83][84]. Sorafenib is a multikinase inhibitor of VEGFR-2/-3, PDGFR-b, B-Raf, and C-Raf; it has shown some level of activity in preclinical models of cholangiocarcinoma.…”

Section: Vegfmentioning

confidence: 99%

“…The California Consortium conducted a phase II study using lapatinib (a dual tyrosine kinase inhibitor of HER2/neu and EGFR pathways) in patients with advanced BTC or hepatobiliary cancer [83]. In all 17 patients recruited into the study, no response was observed.…”

Section: Her2mentioning

confidence: 99%

Molecular Targets in Biliary Carcinogenesis and Implications for Therapy

Oyasiji

Zhang²,

Kuvshinoff³

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Biliary tract cancers (BTCs) encompass a group of invasive carcinomas, including cholangiocarcinoma (intrahepatic, perihilar, or extrahepatic), and gallbladder carcinoma. Approximately 90% of patients present with advanced, unresectable disease and have a poor prognosis. The latest recommendation is to treat advanced or metastatic disease with gemcitabine and cisplatin, although chemotherapy has recorded modest survival benefits.Comprehension of the molecular basis of biliary carcinogenesis has resulted in experimental trials of targeted therapies in BTCs, with promising results. This review addresses the emerging role of targeted therapy in the treatment of BTCs. Findings from preclinical studies were reviewed and correlated with the outcomes of clinical trials that were undertaken to translate the laboratory discoveries. The Oncologist 2015;20:742-751

show abstract

“…Studies of combined sorafenib and gemcitabine, sorafenib, oxaliplatin and capecitabine, or the related antiangiogenic drug sunitinib, also had minimal objective response rates but higher rates of stable disease [46,47,48]. …”

Section: Novel Targets and Therapiesmentioning

confidence: 99%

Current Therapy and Future Directions in Biliary Tract Malignancies

Ciombor

Goff

2013

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

OPINION STATEMENT Cancers of the biliary tree represent a rare group of diseases with a devastating impact on patients. Gallbladder cancer is often associated with cholelithiasis. Cholangiocarcioma may arise in the setting of biliary inflammation such as primary sclerosing cholangitis but most commonly occurs in patients without a particular risk factor. Surgical removal of biliary cancer is essential for cure, but it is associated with a very high rate of recurrence and for many patients is not possible at the time of diagnosis. Although risk factors differ for each anatomic site, systemic treatment is generally similar. Various adjunctive therapies such as radiation and embolization have been investigated for biliary tract cancers with modest success and efforts are ongoing to understand how to optimize these tools. Retrospective series and pooled analysis suggest a benefit for adjuvant treatment following resection, but prospective data is limited. Ongoing and planned phase 3 trials should help clarify the role of adjuvant chemotherapy and radiation. For advanced disease, chemotherapy improves quality of life and survival, and gemcitabine with cisplatin represents the standard of care. However, all patients ultimately progress on this therapy, so clinical trials of new and better agents are essential to expand the existing treatment options for patients.

show abstract

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

Cited by 4 publications

References 0 publications

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Molecular Targets in Biliary Carcinogenesis and Implications for Therapy

Current Therapy and Future Directions in Biliary Tract Malignancies

Contact Info

Product

Resources

About